UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2053-19
Program Prior Authorization/Medical Necessity
Medication Sovaldi® (sofosbuvir)
P&T Approval Date 4/2015, 8/2015, 11/2015, 8/2016, 12/2016, 9/2017, 11/2018, 2/2019,
3/2020, 5/2021, 5/2022, 5/2023, 5/2024, 5/2025
Effective Date 8/1/2025
1. Background:
Sovaldi® (sofosbuvir) is a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor
indicated for the treatment of:
• Adult patients with genotype 1, 2, 3 or 4 chronic hepatitis C virus (HCV) infection without
cirrhosis or with compensated cirrhosis as a component of a combination antiviral treatment
regimen.
• Pediatric patients 3 years of age and older with genotype 2 or 3 chronic HCV infection without
cirrhosis or with compensated cirrhosis in combination with ribavirin.
2. Coverage Criteriaa:
A. For the treatment of chronic hepatitis C genotype 1 or 4 infection in peginterferon eligible
patients who are without cirrhosis or have compensated cirrhosis, Sovaldi in combination
with peginterferon alfa and ribavirin will be approved based on all of the following
criteria:
1. One of the following:
a. Diagnosis of chronic hepatitis C genotype 1 infection
-OR-
b. Diagnosis of chronic hepatitis C genotype 4 infection
-AND-
2. Patient has not experienced failure with a previous treatment regimen that includes
Sovaldi
-AND-
3. Used in combination with peginterferon alfa and ribavirin
-AND-
4. One of the following:
© 2025 United Healthcare Services, Inc.
1
a. Patient is without cirrhosis
-OR-
b. Patient has compensated cirrhosis (Child-Pugh A)
-AND-
5. Physician/provider asserts patient demonstrates treatment readiness, including the ability
to adhere to the treatment regimen
-AND-
6. One of the following:
a. All of the following:
(1) History of intolerance or contraindication to Epclusa (sofosbuvir/velpatasvir)
therapy
-AND-
(2) History of intolerance or contraindication to Harvoni (sofosbuvir/ledipasvir)
therapy
-AND-
(3) History of intolerance or contraindication to Mavyret (glecaprevir/pibrentasvir)
therapy
-AND-
(4) History of intolerance or contraindication to Zepatier (elbasvir/grazoprevir)
therapy
-OR-
b. Patient is currently on Sovaldi therapy
Authorization will be issued for 12 weeks.
B. For the treatment of chronic hepatitis C genotype 1 infection who are without cirrhosis or
have compensated cirrhosis, Sovaldi in combination with ribavirin will be approved based
on all of the following criteria:
1. Diagnosis of chronic hepatitis C genotype 1 infection
© 2025 United Healthcare Services, Inc.
2
-AND-
2. Patient has not experienced failure with a previous treatment regimen that includes
Sovaldi
-AND-
3. Used in combination with ribavirin
-AND-
4. Patient is ineligible for peginterferon alfa therapy
-AND-
5. One of the following:
a. Patient is without cirrhosis
-OR-
b. Patient has compensated cirrhosis (Child-Pugh A)
-AND-
6. Physician/provider asserts patient demonstrates treatment readiness, including the ability
to adhere to the treatment regimen
-AND-
7. One of the following:
a. All of the following:
(1) History of intolerance or contraindication to Epclusa (sofosbuvir/velpatasvir)
therapy
-AND-
(2) History of intolerance or contraindication to Harvoni (sofosbuvir/ledipasvir)
therapy
-AND-
(3) History of intolerance or contraindication to Mavyret (glecaprevir/pibrentasvir)
therapy
© 2025 United Healthcare Services, Inc.
3
-AND-
(4) History of intolerance or contraindication to Zepatier (elbasvir/grazoprevir)
therapy
-OR-
b. Patient is currently on Sovaldi therapy
Authorization will be issued for 24 weeks.
C. For the treatment of chronic hepatitis C genotype 2 infection who are without cirrhosis or
have compensated cirrhosis, Sovaldi in combination with ribavirin will be approved based
on all of the following criteria:
1. Diagnosis of chronic hepatitis C genotype 2 infection
-AND-
2. Patient has not experienced failure with a previous treatment regimen that includes
Sovaldi
-AND-
3. Used in combination with ribavirin
-AND-
4. One of the following:
a. Patient is without cirrhosis
-OR-
b. Patient has compensated cirrhosis (Child-Pugh A)
-AND-
5. Physician/provider asserts patient demonstrates treatment readiness, including the ability
to adhere to the treatment regimen
-AND-
6. One of the following:
a. Both of the following:
(1) History of intolerance or contraindication to Epclusa (sofosbuvir/velpatasvir)
© 2025 United Healthcare Services, Inc.
4
therapy
-AND-
(2) History of intolerance or contraindication to Mavyret (glecaprevir/pibrentasvir)
therapy
-OR-
b. Patient is currently on Sovaldi therapy
Authorization will be issued for 12 weeks.
D. For the treatment of chronic hepatitis C genotype 3 infection who are without cirrhosis or
have compensated cirrhosis, Sovaldi in combination with ribavirin will be approved based
on all of the following criteria:
1. Diagnosis of chronic hepatitis C genotype 3 infection
-AND-
2. Patient has not experienced failure with a previous treatment regimen that includes
Sovaldi
-AND-
3. Used in combination with ribavirin
-AND-
4. One of the following:
a. Patient is without cirrhosis
-OR-
b. Patient has compensated cirrhosis (Child-Pugh A)
-AND-
5. Physician/provider asserts patient demonstrates treatment readiness, including the ability
to adhere to the treatment regimen
-AND-
6. One of the following:
© 2025 United Healthcare Services, Inc.
5
a. Both of the following:
(1) History of intolerance or contraindication to Epclusa (sofosbuvir/velpatasvir)
therapy
-AND-
(2) History of intolerance or contraindication to Mavyret (glecaprevir/pibrentasvir)
therapy
-OR-
b. Patient is currently on Sovaldi therapy
Authorization will be issued for 24 weeks.
E. For the treatment of chronic hepatitis C genotype 1, 2, 3, or 4 infection in patients with
hepatocellular carcinoma awaiting liver transplantation. Sovaldi in combination with
ribavirin will be approved based on all of the following criteria:
1. Diagnosis of hepatocellular carcinoma
-AND-
2. Patient is an active candidate on the waiting list for a liver transplant
-AND-
3. Patient is being managed in a liver transplant center
-AND-
4. Patient has not experienced failure with a previous treatment regimen that includes
Sovaldi
-AND-
5. Used in combination with ribavirin
-AND-
6. Physician/provider asserts patient demonstrates treatment readiness, including the ability
to adhere to the treatment regimen
-AND-
7. One of the following:
© 2025 United Healthcare Services, Inc.
6
a. Both of the following:
(1) Diagnosis of chronic hepatitis C genotype 1or 4
-AND-
(2) One of the following:
(a) Both of the following:
• History of intolerance or contraindication to Harvoni
(sofosbuvir/ledipasvir) therapy
• History of intolerance or contraindication to Epclusa
(sofosbuvir/velpatasvir) therapy
-OR-
(b) Patient is currently on Sovaldi therapy
-OR-
b. Both of the following:
(1) Diagnosis of chronic hepatitis C genotype 2 or 3
-AND-
(2) One of the following:
(a) History of intolerance or contraindication to Epclusa
(sofosbuvir/velpatasvir) therapy
-OR-
(b) Patient is currently on Sovaldi therapy
Authorization will be issued for 48 weeks.
a. State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply Limits may be in place.
© 2025 United Healthcare Services, Inc.
7
4. References:
1. Sovaldi [package insert]. Foster City, CA: Gilead Sciences, Inc.; March 2020.
2. American Association for the Study of Liver Diseases and the Infectious Diseases Society of
America. Recommendations for Testing, Managing, and Treating Hepatitis C.
http://www.hcvguidelines.org/full-report-view. Accessed April 10, 2025.
Program Prior Authorization/Medical Necessity - Sovaldi (sofosbuvir)
Change Control
4/2015 Coverage requirements for State of New Jersey effective 5/18/15.
8/2015 Added criteria for combination therapy with Daklinza (daclatasvir).
11/2015 Revised criteria to remove Sovaldi plus ribavirin step for cirrhotic
patients in section M, merged section N into M, changed program title to
include all lines of business and updated language regarding
documentation of liver fibrosis.
7/2016 Added Indiana and West Virginia coverage information.
8/2016 Updated criteria to include Eplcusa as well as revisions to peginterferon
eligibility requirements.
10/2016 Administrative change to correct formatting.
10/2016 Administrative change made for clarity.
11/2016 Added California coverage information.
12/2016 Removed abstinence-based criteria and replaced with treatment readiness
screening criteria.
5/2017 Administrative update to reorder criteria. State mandate reference
language updated.
9/2017 Revised step therapy criteria based on new product availability, included
NY prescriber requirement, removed treatment readiness screening tools
and removed medical record submission requirements.
11/2018 Annual review. Removed Olysio. Updated references.
2/2019 Revised step therapy to include Zepatier for genotypes 1 & 4.
3/2020 Annual review. Removed Daklinza as product is no longer available in
market. Added requirement for peg-interferon ineligibility for genotype 1
+ RBV. Removed Sovaldi + RBV for 24 weeks for GT 4 to align with
current label and recommendations.
5/2021 Annual review. Removed prescriber requirement. Updated references.
5/2022 Reformatted criteria. Updated references.
5/2023 Annual review. Simplified peginterferon eligibility requirements.
Clarified generic names for Harvoni and Epclusa. Updated references.
5/2024 Annual review. Removed liver disease staging criteria that was included
for quality purposes rather than part of coverage decision. Updated
references.
5/2025 Annual review without changes to coverage criteria. Updated references.
© 2025 United Healthcare Services, Inc.
8